Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Palatin Technologies, a biopharmaceutical company, has extended its exclusive research collaboration and licensing agreement with AstraZeneca to discover, develop and commercialize compounds that target melanocortin receptors. The company has also signed a clinical trial sponsored research agreement.
Subscribe to our email newsletter
Under the extension to the licensing agreement, Palatin will receive an upfront payment of $1.6 million and AstraZeneca has been granted licenses to additional compounds and patents.
Additionally, the research collaboration term has been extended, with Palatin contributing scientific expertise and AstraZeneca supporting Palatin’s internal activities at an agreed full-time equivalent rate.
Under the clinical trial sponsored research agreement, Palatin will be responsible for conducting a study of the effects of melanocortin receptor specific compounds on food intake, obesity and other metabolic parameters. Palatin will be eligible, in the near future, for milestone payments totaling $5 million in connection with the collaboration and licensing agreement.
Stephen Wills, Palatin’s executive vice president of operations and CFO, said: “The license extension and clinical trial agreements point to the progress Palatin and AstraZeneca have made with their collaborative melanocortin receptor obesity program. Of the total $6.6 million due from AstraZeneca, we anticipate receiving $4.1 million by December 31, 2008 and the remaining $2.5 million in the first quarter of calendar year 2009.”